CAV1 and neoplasm: In vivo, a combination of anti-CAV1 antibody treatment along with dasatinib or sunitinib demonstrated significant tumor regression when compared to the drug treatment alone [90], suggesting the importance of drug combinations in overcoming treatment resistance.